NeuroVenti contributes to creating a society where we work together.

  • 2015
    • 07Establishment of the corporation
  • 2016
    • 04CDRO (drug screening) project order (150 Million KRW)
  • 2017
    • 06Selected for Industry-University-Research Cooperation technology development project by Ministry of SMEs and Startups (MSS)
    • 06Selected for Tech Incubator Program for Startup Korea (TIPS) project by MSS
  • 2018
    • 08Selected as a resident startup of Seoul Bio Hub
  • 2020
    • 01NV01-A02 patent application
    • 07Series A financing
    • 09Selected for AI voucher support project by National IT Industry Promotion Agency
  • 2021
    • 05Completion of NV01-A02 efficacy studies
    • 06Completion of NV01-A03 efficacy studies
    • 08NV01-A02, selected as candidate for ASD
    • 08Relocation of headquarter office to Gangnam-gu
    • 11CDRO (depression drug efficacy) project order (76 Million KRW)
    • 11Awarded as an excellent health and medical technology company by Korea Health Industry Development Institute (KHIDI)
  • 2022
    • 07Awarded as a Korea excellent patent by Hankookilbo and Korea Institute of Patent Information (KIPI)
    • 07CDRO (ADHD drug efficacy) project order (36 Milllion KRW)
    • 10US FDA Approved for ODD, the first FXS treatment
    • 12Selected as a non-face-to-face service voucher demand company